MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Allow Me to Reintroduce Myself: Hologic Gets Back to Basics After Cynosure

The Marlborough, MA-based company presented its plan for success at the 38th annual J.P. Morgan Healthcare Conference, announcing it would pursue more tuck-in deals and invest in share buybacks. The plans come a few weeks after Hologic’s divested the Cynosure medical aesthetics business, which had been underperforming.

Image by Drew Beamer on  Unsplash

Women’s Health company, Hologic seems to be finished with “big” medtech acquisitions for the near future – instead, turning to tuck-in deals to drive growth. In a presentation titled “Reintroducing a Unique Asset in Women’s Health, the Marlborough, MA-based company’s CEO Steve MacMillan spoke to investors and analysts Monday during the 38th annual J.P. Morgan Healthcare Conference.

“We intend to deploy our strong-free cashflow more aggressively on growth accretive tuck-in deals, not huge deals … and also on share buybacks because we believe in our future,” MacMillan said.

Hologic’s board announced on Sunday the approval of a new $500 million share repurchase program.

The switch to smaller deals is perhaps a direct result of Hologic’s acquisition and subsequent divestiture of Cynosure. Hologic acquired Cynosure for $1.65 billion in 2017 but divested the company to an affiliate of investment funds managed by Clayton, Dubilier & Rice for $205 million. The medical aesthetics business had been draining for Hologic and constantly under-performed.

“Divesting Cynosure did remove that overhang,” he said. “Obviously a deal we would not do again, but we also recognized it, took action and moved forward.”

In preliminary earnings released Sunday, the company said it expects to report total revenues of about $850.5 million, an increase of 2.4% compared to the prior-year period, or 2.8% in constant currency. This was above the consensus Wall Street estimate of $839.2 million. These preliminary results compare to Hologic’s most recent guidance range of $835 million to $850 million, which was provided on Nov. 6, 2019.

The highlight of the preliminary earnings was Hologic’s surgical business, which saw strong growth. In preliminary earnings for the most recent quarter, Hologic posted revenue of $119 million compared to the $108.4 million the company posted this time last year.

MacMillan said at one point Hologic’s surgical business was just not in “good shape.”

"We just posted 10% growth in our surgical business,” MacMillan said. “One that many had given up for dead many years ago.”

 

Filed Under
500 characters remaining